ACELYRIN Inc

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Acelyrin Inc reports strong Q2 results, optimistic on transformative medicines

Acelyrin Inc showcased positive trial data for izokibep in HS and PsA, emphasizing transformative medicines
Company's strong financial position post-IPO and detailed responses on key program benefits
Analyst questions highlighted focus on trial timelines, differentiation, and dosing strategies
Overall positive outlook on pipeline and commitment to delivering innovative medicines

Acelyrin reports strong Q2 results, focuses on lonigutamab progress

Acelyrin Inc (SLRN) showcased positive performance in key drug programs and financial sustainability measures during Q2 2024.
While facing challenges such as workforce reductions and tinnitus cases, the company remains well-positioned for growth and clinical advancement.
Opportunities lie in engaging with regulators, sharing program updates, and leveraging their cash position for strategic expansion.
Investors can expect continued progress and transparency from Acelyrin as they navigate clinical milestones and investor engagements.

Acelyrin Inc advances lonigutamab towards Phase III, bolstered by financial strength

Acelyrin Inc's Q3 performance highlights progress in clinical development, financial stability, and strategic planning for future growth.
While facing challenges in dose announcements and study design details, the company's strengths in FDA alignment, financial flexibility, and proactive engagement present opportunities for expansion and success.
Overall, Acelyrin's positive momentum in product development and regulatory milestones positions them favorably for continued advancement and potential market impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Acelyrin, Inc. (NASDAQ:SLRN ) Q3 2024 Earnings Call November 13, 2024 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations and Corporate Affairs Mina Kim - Chief Executive Officer Gil Labrucherie - Chief Financial Officer and Chief Business Officer Shephard Mpofu - Chief Medical Officer Conference Call Participants Tyler Van Buren - TD Cowen Emily Bodnar - H.C. Wainwright Vikram Purohit - Morgan Stanley Samantha Semenkow - Citi Operator Good afternoon, and welcome to the Acelyrin, Inc. Third Quarter 2024 Financial Results and Company Update Conference Call.

Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript

Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Wednesday, November 13, 2024 at 4:30 p.m. ET to discuss its third quarter 2024 financial results and other corporate updates.

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

Acelyrin, Inc. shifts focus to developing lonigutamab for thyroid eye disease, aiming for phase 3 trials in Q1 2025, bypassing phase 2b/3 studies. Key catalysts include an end-of-phase 2 meeting and additional phase 2 data by the end of 2024, potentially boosting shareholder value. Lonigutamab offers a competitive edge with subcutaneous administration, higher potency, and lower adverse events compared to other anti-IGF-1R therapies.

Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch

LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive results from the company's global Phase 3 clinical trial of izokibep in moderate-to-severe hidradenitis suppurativa (HS) patients will be shared as a late-breaking oral presentation at the 2024 European Academy of Dermatology and Venereology taking place September 25-28, 2024 in Amsterdam, Netherlands. Presentation details are as follows:

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that members of its management team will participate in fireside chats and 1x1 meetings at the following investor conferences:

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

On Wednesday, Acelyrin Inc. SLRN confirmed that it was completing a 33% reduction in its workforce.

Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep

Acelyrin, Inc. (NASDAQ:SLRN ) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Tyler Marciniak - Vice President of Investor Relations and Corporate Affairs Mina Kim - Chief Executive Officer Shep Mpofu - Chief Medical Officer Gil Labrucherie - Chief Financial Officer and Chief Business Officer Conference Call Participants Derek Archila - Wells Fargo Tyler Van Buren - TD Cowen Yasmeen Rahimi - Piper Sandler Phoebe Tan - Jefferies Emily Bodnar - H.C. Wainwright Vikram Purohit - Morgan Stanley Samantha Semenkow - Citi Operator Good afternoon, and welcome to the ACELYRIN INC.

Acelyrin, Inc. (SLRN) Q2 2024 Earnings Call Transcript

LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, August 13, 2024 at 5:00 p.m. ET to discuss its second quarter 2024 financial results and provide a corporate update.

ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

Lonigutamab is the first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease (TED) patients

ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024

Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by end of third and fourth quarter of 2024, respectively

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Monday, May 13, 2024 at 4:30 p.m. ET to discuss its first quarter 2024 financial results and provide a corporate update.

ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024

Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients

ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

ACELYRIN (SLRN) posts positive proof-of-concept data from a phase I/II study evaluating its pipeline candidate, lonigutamab, for treating thyroid eye disease. Stock gains.

ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study

Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32

ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients

Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies

ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

NEW YORK , Jan. 16, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Acelyrin, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Acelyrin investors who were adversely affected by alleged securities fraud between May 4, 2023 and September 11, 2023.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Acelyrin, Inc.(SLRN) Investors of a Class Action Lawsuit and Upcoming Deadline

LOS ANGELES, CA / ACCESSWIRE / January 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 15, 2024.

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 15, 2024.

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, Jan. 15, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ACELYRIN, Inc. ("Acelyrin" or "the Company") (NASDAQ: SLRN) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Acelyrin securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period").

FINAL SLRN DEADLINE: Bronstein, Gewirtz & Grossman LLC Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK , Jan. 14, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acelyrin, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN) and certain officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 23-cv- 09672, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acelyrin securities between May 4, 2023 and September 11, 2023, both dates inclusive (the "Class Period").

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acelyrin, Inc. of Class Action Lawsuit and Upcoming Deadline - SLRN

RADNOR, Pa. , Jan. 12, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been against Acelyrin, Inc. ("Acelyrin") (NASDAQ: SLRN).

SLRN Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Acelyrin, Inc. (SLRN) of Deadline in Securities Fraud Class Action Lawsuit

NEW YORK , Jan. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Acelyrin, Inc.. Shareholders who purchased shares of SLRN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN)

LOS ANGELES, CA / ACCESSWIRE / January 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 15, 2024.

News for ACELYRIN Inc Stock (SLRN)